Indie has found relief from her epilepsy symptoms with Bedrocan's medical cannabis. This is the story of her family's struggle to get her the medicine she needs
European Cannabis- The week in Review. German distribution, Danish cultivation and the ever changing world of cannabis testing.
Medical cannabis has been legal since November 1st 2018 and yet patients are still having difficulty accessing products. We sat down with two companies, one big one small, who want to fill that gap.
Recently, Europe has been showing an interesting potential
in the Cannabis market.
The medical cannabis market in Europe could double in size in 2019. By 2028, the value of this flourishing market is estimated to be worth €123bn. There have been many exciting developments in the last week that lend credence to these projection.
Following on from becoming the first Asian country to legalise medical cannabis in November. South Korean Authorities announced last Tuesday that the country would be accepting its first shipment of medical cannabis next month.
Cannabidiol or CBD has been getting a lot of press lately. This substance from the cannabis plant is generally regarded as non-intoxicating, with the feeling of being high associated with consumption of tetrahydrocannabinol aka THC.
Professor Nutt's scheduled debate became a lecture when the Royal College of Psychiatrists could find no one to oppose him! Click to view
Today’s article in the Spectator may have read very differently if the Author had heard the President’s Lecture at the Royal College of Psychiatrists (RCP) On Wednesday, Professor David Nutt took on one of the greatest challenges in drug reform advocacy, explaining to a room full of psychiatrists that a regulated cannabis market would be better for society than the current black market. It’s a tough sell. Psychiatrists are notoriously anti-cannabis legalisation, (although the RCP have announced they are reviewing that stance) and it’s not hard to see why: their patients are unwell and exhibit a higher rate of cannabis...
Source: Canopy Growth Spectrum Biomedical UK (Spectrum UK) is a newly formed company focused on providing access of cannabis-based medicinal products to UK patients with severe clinical unmet need. The joint venture between Canopy Growth Corporation (Canopy Growth) (TSX: WEED) (NYSE: CGC) and Beckley Canopy Therapeutics (Beckley Canopy) will be the exclusive distributor of Spectrum Cannabis medicinal products in the UK market.
The risks of strong cannabis means we need to regulate more than ever
Figures for NHS England will be released in March but it’s expected to be disappointingly low according to patient groups. We should have official figures on how many medical cannabis patients at the end of March according to the Health secretary, Steve Brine. If the government can keep to its timeline, which is unlikely to happen as it would have the numbers announced at the same time as Brexit, when all government departments are likely to be occupied, we will still be missing key insight. The government figures won’t include ‘the number of patients denied access to prescriptions for medicinal...